The trading price of Calidi Biotherapeutics Inc (AMEX:CLDI) closed lower on Monday, July 07, and closing at $0.24, -2.28% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $0.224899 and $0.26. In examining the 52-week price action we see that the stock hit a 52-week high of $3.89 and a 52-week low of $0.20. Over the past month, the stock has lost -34.14% in value.
Calidi Biotherapeutics Inc, whose market valuation is $7.63 million at the time of this writing, is expected to release its quarterly earnings report on 2025-May-14. Investors’ optimism about the company’s current quarter earnings report is understandable.
On the technical side, indicators suggest CLDI has a 100% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
A quick review shows that CLDI’s price is currently -14.99% off the SMA20 and -34.87% off the SMA50. The RSI metric on the 14-day chart is currently showing 29.46, and weekly volatility stands at 8.46%. When measured over the past 30 days, the indicator reaches 12.53%. Calidi Biotherapeutics Inc (AMEX:CLDI)’s beta value is currently sitting at 0.94. With analysts defining $2-$9 as the low and high price targets, we arrive at a consensus price target of $5.5 for the trailing 12-month period. The current price is about -733.33% off the estimated low and -3650.0% off the forecast high, based on this estimate. Investors will be thrilled if CLDI’s share price rises to $5.5, which is the median consensus price. At that level, CLDI’s share price would be -2191.67% below current price.
To see how Calidi Biotherapeutics Inc stock has been performing in comparison to its peers in the industry, here are the numbers: CLDI stock’s performance was -2.28% in the latest trading, and -79.11% in the past year.
An evaluation of the daily trading volume of Calidi Biotherapeutics Inc (AMEX:CLDI) indicates that the 3-month average is 778.37K. However, this figure has increased over the past 10 days to an average of 2.93.
Currently, records show that 31.79 million of the company’s shares remain outstanding. The insiders hold 6.57% of outstanding shares, whereas institutions hold 17.13%. The stats also highlight that short interest as of 2025-06-13, stood at 0.37 million shares, resulting in a short ratio of 0.74 at that time. From this, we can conclude that short interest is 126.00 of the company’s total outstanding shares. It is noteworthy that short shares in June were up slightly from the previous month’s figure, which was 0.27 million. However, since the stock’s price has seen -88.13% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
